EVALUATION OF WHOLE ABDOMINAL IRRADIATION IN OVARIAN-CARCINOMA WITH A 4 ORTHOGONAL FIELDS TECHNIQUE

被引:12
作者
THOMAS, L
PIGNEUX, J
CHAUVERGNE, J
STOCKLE, E
BUSSIERES, E
CHEMIN, A
TOULOUSE, C
机构
[1] FDN BERGONIE,CTR COMPREHENS CANC,DEPT MED ONCOL,F-33076 BORDEAUX,FRANCE
[2] FDN BERGONIE,CTR COMPREHENS CANC,DEPT SURG,F-33076 BORDEAUX,FRANCE
[3] FDN BERGONIE,CTR COMPREHENS CANC,DEPT BIOSTAT,F-33076 BORDEAUX,FRANCE
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1994年 / 30卷 / 05期
关键词
OVARIAN CARCINOMA; 4 ORTHOGONAL FIELDS TECHNIQUE; WHOLE ABDOMINAL IRRADIATION;
D O I
10.1016/0360-3016(94)90313-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The purpose of this study is to evaluate the toxicity and the results of abdominopelvic irradiation with a four orthogonal field's technique in patients with ovarian carcinoma. Methods and Materials: Between May 1981 and December 1990, 167 patients with ovarian carcinoma have been treated with whole abdominal irradiation: 62 patients with no or minimal residual disease < 2 cm after initial surgery (group 1) and 105 patients with no residual disease or macroscopic residual disease < 2 cm assessed by second-look surgery after incomplete debulking surgery and cisplatin-based polychemotherapy (group 2). Irradiation was performed by a four orthogonal field's technique. Thirty grays were given with a 25 MV photon beam (1.5 Gy/fraction/day, 20 fractions over 30 days). Boosts were performed in 50 cases (median dose of 15 Gy). Results: With a median follow-up of 68 months, the 5-year actuarial survival rate was 50% in the entire group, 67% in group 1, 40% in group 2, and 84% in T1, 61.5% in T2, 38% in T3. Five-year actuarial survival was analyzed according to the residuum: (a) after initial surgery (no residual disease: 70%, residual disease: 36.5%), (b) after second-look surgery: 76% in patients with a negative second look, 66% in patients with microscopic residual disease, 22% in patients with macroscopic residual disease and secondary surgical reduction, and 10% in patients with small unresectable nodules. Nine percent of the patients failed to complete irradiation acute side effects related. Five percent required surgery for bowel obstruction. Conclusion: The abdominopelvic irradiation with this four orthogonal field's technique was associated with tolerable acute toxicity and a low risk of serious late complications. Similar late results to have been reported whole abdominal irradiation with chemotherapy in patients with negative or microscopic residual disease after surgery. Randomized trials comparing these two adjuvant treatments are warranted.
引用
收藏
页码:1083 / 1090
页数:8
相关论文
共 48 条
[1]   THE IMPACT OF WHOLE-ABDOMEN RADIOTHERAPY ON SURVIVAL IN ADVANCED OVARIAN-CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE AFTER CHEMOTHERAPY [J].
BOLIS, G ;
ZANABONI, F ;
VANOLI, P ;
RUSSO, A ;
FRANCHI, M ;
SCARFONE, G ;
PECORELLI, S .
GYNECOLOGIC ONCOLOGY, 1990, 39 (02) :150-154
[2]   CHEMOTHERAPY VERSUS RADIOTHERAPY IN THE MANAGEMENT OF OVARIAN-CANCER PATIENTS WITH PATHOLOGICAL COMPLETE RESPONSE OR MINIMAL RESIDUAL DISEASE AT 2ND LOOK [J].
BRUZZONE, M ;
REPETTO, L ;
CHIARA, S ;
CAMPORA, E ;
CONTE, PF ;
ORSATTI, M ;
VITALE, V ;
RUBAGOTTI, A ;
ROSSO, R .
GYNECOLOGIC ONCOLOGY, 1990, 38 (03) :392-395
[3]   WHOLE ABDOMEN RADIATION FOR MINIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA AFTER SURGICAL RESECTION AND MAXIMAL 1ST-LINE CHEMOTHERAPY [J].
CAIN, JM ;
RUSSELL, AH ;
GREER, BE ;
TAMIMI, HK ;
FIGGE, DC .
GYNECOLOGIC ONCOLOGY, 1988, 29 (02) :168-175
[4]  
CHASSAGNE D, 1980, B CANCER, V67, P1
[5]  
CHAUVERGNE J, 1974, B CANCER, V61, P235
[6]  
Chauvet B, 1989, J Gynecol Obstet Biol Reprod (Paris), V18, P526
[7]   A RANDOMIZED TRIAL COMPARING CISPLATIN PLUS CYCLOPHOSPHAMIDE VERSUS CISPLATIN, DOXORUBICIN, AND CYCLOPHOSPHAMIDE IN ADVANCED OVARIAN-CANCER [J].
CONTE, PF ;
BRUZZONE, M ;
CHIARA, S ;
SERTOLI, MR ;
DAGA, MG ;
RUBAGOTTI, A ;
CONIO, A ;
RUVOLO, M ;
ROSSO, R ;
SANTI, L ;
CARNINO, F ;
COTTINI, M ;
MOSSETTI, C ;
GUERCIO, E ;
GATTI, M ;
SILIQUINI, PN ;
PRELATO, ML ;
DURANDO, C ;
GIACCONE, G ;
CALCIATI, A ;
FARININI, D ;
CENTONZE, M ;
RUGIATI, S ;
PARODI, G ;
MESSINEO, M ;
STORACE, A ;
BERNARDINI, G ;
MISURALE, F ;
ALESSANDRI, S ;
CASINI, M ;
RAGNI, N ;
FOGLIA, G ;
BENTIVOGLIO, G ;
PESCETTO, G .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (06) :965-971
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]   2ND-LOOK LAPAROTOMY IN THE PATIENT WITH MINIMAL RESIDUAL STAGE-III OVARIAN-CANCER (A GYNECOLOGIC ONCOLOGY GROUP-STUDY) [J].
CREASMAN, WT ;
GALL, S ;
BUNDY, BN ;
BEECHAM, J ;
MORTEL, R ;
HOMESLEY, HD .
GYNECOLOGIC ONCOLOGY, 1989, 35 (03) :378-382
[10]  
DAUPLAT J, 1990, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V19, P247